ATAP-M8 approved by China's CDE to enter human clinical trials in advanced solid tumors
Phase II SBIR grant awarded to advance MG53 commercialization in wound healing
New MG53 studies reported in corneal injury and valvular heart disease
Founder Dr. Jianjie Ma presented at TEDxColumbus: On The Edge
Phase I SBIR grant awarded for MG53 proof-of-concept studies in wound healing
Phase II SBIR grant awarded by NIH for a total of $1.8 million
New TRIM-edicine website launched
人民网：“细胞修理工”或可预防急性肾损伤
MG53-mediated membrane repair study in acute kidney injury published in Science Translational Medicine
人民网：新型蛋白MG53能像“创可贴”一样即时修复“伤口”
NIH-SBIR grant awarded to support preclinical development of MG53
MG53-mediated cell membrane repair study in acute lung injury published in Nature Communications
SMARTT award from NHLBI supports CMC development
NIH-NCI SBIR Phase I grant awarded for ATAP-mediated apoptosis in prostate cancer
Pre-IND meeting held with FDA on therapeutic use of recombinant MG53
U.S. patent awarded on serum MG53 as a diagnostic marker for tissue injury
New R&D facility established at the TechColumbus Technology Center in Columbus, Ohio
$1.5 million NIH SBIR Phase II award supports protein therapeutics in muscular dystrophy
MG53, cell membrane repair and muscular dystrophy findings featured on the cover of Science Translational Medicine
中新网：“美华裔研究蛋白修复获大突破 成立药厂开发新药”
Founder Dr. Jianjie Ma featured in The Star-Ledger: “In UMDNJ lab, discovery could boost body’s resilience”
Dr. Noah Weisleder received the 2011 Kauffman Foundation Postdoctoral Entrepreneur Award
New provisional patent application filed for diagnostic biomarkers of tissue injury
Qualifying Therapeutic Discovery Project grant awarded for muscular dystrophy protein therapeutics
SBIR grant awarded for protein therapeutics for muscular dystrophy
TRIM-edicine joined the Biotechnology Industry Organization
New R&D facility opened at the Commercialization Center for Innovative Technology in North Brunswick, New Jersey
New Jersey Commission on Science and Technology awarded $500,000 for product development with Colgate-Palmolive
Licensing agreement signed with UMDNJ-Robert Wood Johnson Medical School to commercialize technology from the laboratory of Dr. Jianjie Ma
